Cargando…
Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma
Recently, bendamustine has become an important agent in the treatment for patients with lymphoid malignancies. Although the drug has received approval for second-line therapy in indolent lymphoma, a growing body of evidence suggests its efficacy and safety in first-line use. The results of randomise...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006123/ https://www.ncbi.nlm.nih.gov/pubmed/24752517 http://dx.doi.org/10.1007/s12032-014-0944-1 |